Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Medios AG is a leading provider of specialty pharmaceutical solutions in Germany, specializing in the supply of high-priced medications for rare and chronic diseases. Founded in 2015 and headquartered in Berlin, the company operates primarily through two key segments: Pharmaceutical Supply and Patient-Specific Therapies. The Pharmaceutical Supply segment delivers over 1,000 products targeting critical therapeutic areas including oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia, ensuring reliable access for specialized pharmacies, hospitals, and medical specialists. The Patient-Specific Therapies segment, GMP-certified with advanced cleanrooms, compounds approximately 400,000 individualized preparations annually, such as cytostatic infusions, antibody therapies, virostatic and antibiotic medications, parenteral nutrition solutions, and investigational medicinal products for clinical trials. Medios AG maintains stringent quality standards with temperature-controlled logistics from -80°C to +25°C and supports a Europe-wide network for optimized patient care in individualized medicine. As Germany's market leader in this sector, it plays a pivotal role in enhancing pharmaceutical supply chains for complex disorders.